Engflag

Azilsartan

Quick links to important sections

Azilsartan

Azilsartan_DA

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azilsartan

Property Description
Active ingredient Azilsartan medoxomil (Prodrug)
Form Tablets (Oral administration)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic hypertension management
Origin Synthetic compound

Azilsartan: Defining the Angiotensin II Receptor Blocker Class

Azilsartan is a prescription-only medication classified as a synthetic compound used for the systemic management of high blood pressure. It belongs to the Angiotensin II Receptor Blocker (ARB) pharmacological class. This group of agents is designed to control elevated blood pressure through a targeted interaction with the circulatory system. Azilsartan is distinguished by its function as a non-peptide antagonist, ensuring that the medication's effect is focused on regulating arterial tension. Azilsartan has a notably potent and persistent ability to inhibit the targeted receptors compared to some older ARBs.

Composition and Form: The Azilsartan Medoxomil Prodrug

The core active component is Azilsartan medoxomil, which is the chemical substance (INN) present in the final oral tablets. This substance functions as a prodrug, meaning it is initially inactive but is specifically designed to be metabolically converted into its true therapeutic agent, Azilsartan carboxylic acid, once absorbed into the body. Delivered as a single-ingredient product, the tablets are formulated for efficient absorption via the oral route of administration. The drug’s design achieves a high level of bioavailability, which is critical for the reliable systemic delivery of the active metabolite.

Primary Purpose: Regulating Systemic Hypertension

The general therapeutic purpose of Azilsartan is the long-term stabilization of blood pressure in adults diagnosed with systemic hypertension. The drug works by specifically blocking the effects of the powerful vasoconstrictive hormone Angiotensin II on the blood vessels, promoting vascular relaxation. This physiological action results in a reduction of peripheral resistance within the arteries, which is the foundational effect required to achieve and maintain healthy blood pressure management. The outcome is the systematic reduction of mechanical strain on the heart and major blood vessels.

What side effects are possible with Azilsartan?

Possible Side Effects and Safety Information: Azilsartan

Azilsartan's official safety profile is strongly defined by risks related to pregnancy and specific patient conditions, as documented in regulatory sources.

Serious Safety Concerns and Restrictions

The medicine carries a Boxed Warning regarding fetal toxicity. Use during the second and third trimesters of pregnancy is strictly contraindicated as it can cause injury and death to a developing fetus. Use during the first trimester is not recommended.

Use is contraindicated with aliskiren-containing products in patients with diabetes mellitus or those with moderate to severe kidney impairment (GFR less than 60 mL/min/1.73 m^2).

Clinically significant adverse reactions include Angioedema (swelling of the face, lips, throat, and tongue) and Symptomatic Hypotension (excessive low blood pressure), particularly in patients with pre-existing volume or salt depletion (e.g., from high-dose diuretics or diarrhea) or severe kidney impairment.

Common Adverse Reactions

Adverse reactions reported as common in clinical trials include:

  • Dizziness
  • Diarrhea
  • Nausea
  • Fatigue
  • Asthenia (lack of energy or physical strength)
  • Cough

Regulatory Context

Patients with volume or salt depletion, severe congestive heart failure, or severe renal impairment are identified as high-risk groups requiring careful monitoring of blood pressure, serum potassium, and renal function upon treatment initiation. The overall safety structure emphasizes the severe reproductive hazard and restrictions on use in specific high-risk patient populations and in combination with certain other blood pressure medications.

Overdose and Emergency Response

Azilsartan Overdose and When to Seek Help

Overdose with Azilsartan primarily causes effects related to its blood pressure-lowering action, according to regulatory information. The most likely documented manifestation is hypotension (low blood pressure), which may be accompanied by changes in heart rate, such as tachycardia (fast heart rate) or, less commonly, bradycardia (slow heart rate).

Documented Emergency Response

The most serious outcome is symptomatic hypotension, which requires immediate attention. Patients or caregivers should seek urgent medical help (call emergency services) if the individual has collapsed, is having trouble breathing, has had a seizure, or cannot be awakened.

Overdose Action Regulatory Guidance
Immediate Action Initiate supportive treatment; place the patient in the supine position.
Symptomatic Management If symptomatic hypotension occurs, administer intravenous infusion of normal saline (0.9% sodium chloride) to restore volume.
Antidote/Removal No specific antidote exists. Azilsartan is not dialyzable (cannot be removed by hemodialysis).

Clinical Management Profile

Management of Azilsartan overdose is strictly supportive and focused on stabilizing blood pressure and vital signs until the drug is naturally eliminated from the body. Since the drug is not dialyzable, all efforts concentrate on addressing the acute clinical manifestations, particularly restoring adequate blood pressure and circulation.

Therapeutic Uses of Azilsartan

What Azilsartan treats: Main Uses and Benefits

Azilsartan is generally used to help with conditions marked by increased physiological stress, specifically the symptoms related to persistent systemic imbalance known as high blood pressure. Its primary role is applied across domains involving the ongoing management of essential hypertension in adults.

The therapeutic focus is relevant for easing the persistent elevation of blood pressure readings, specifically supporting the management of both the systolic and diastolic measurements. The medication is applied in addressing situations that require supportive and comprehensive pressure management, including monotherapy for chronic high blood pressure and use in combination therapy. This approach may assist with addressing systemic cardiovascular risk factors associated with chronic high pressure.

It is also commonly used to help with co-existing conditions such as Type 2 Diabetes Mellitus, where managing pressure is important for supporting the overall systemic burden. A primary therapeutic support provided by Azilsartan is the management of persistent elevation of blood pressure readings, which contributes to easing functional stress on target organs like the brain, heart, and kidneys.

Quick Fact: Therapeutic Support for Elevated Blood Pressure A primary therapeutic support provided by Azilsartan is the management of persistent elevation of blood pressure readings, which contributes to easing functional stress on target organs like the brain, heart, and kidneys.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Azilsartan is officially indicated for use in adults to treat high blood pressure. Regulatory documentation strictly defines populations for whom the medicine is restricted or prohibited.

Contraindicated Populations

Azilsartan must not be used in the following groups:

  • Patients with hypersensitivity to azilsartan or any of the product's components.
  • Women in the second and third trimesters of pregnancy. Official labels recommend immediate discontinuation upon detection of pregnancy.
  • Patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2) who are concurrently taking aliskiren-containing products.

Use Restrictions and Special Considerations

Use is not recommended or requires caution in several groups due to insufficient data or increased risk:

  • Pediatric population (under 18 years of age) is excluded as safety and efficacy have not been established.
  • Patients with severe hepatic impairment; use has not been studied.
  • Patients with severe renal impairment or end-stage renal disease, or those with recent kidney transplantation, require caution due to limited or no experience of use.
  • Patients with intravascular volume or salt depletion must have the condition corrected or be supervised closely when starting treatment.
  • Breastfeeding women are generally advised against use, as per official labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Azilsartan's co-administration with certain products requires careful clinical management based on official regulatory documents. The primary interactions involve agents that affect kidney function, potassium levels, or certain drug clearances.

Documented Interacting Categories

Category Interaction Implication Required Constraint/Monitoring
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce antihypertensive effect; increased risk of worsening renal function. Monitoring of renal function and blood pressure is required.
Potassium-Sparing Diuretics / Potassium Supplements Increased risk of hyperkalemia (abnormally high potassium levels in the blood). Serum potassium levels must be carefully monitored.
Diuretics (e.g., Thiazides) Increased risk of symptomatic hypotension and acute renal failure, especially upon initiation. Monitoring for signs of volume depletion or renal impairment.
Lithium Reduced renal clearance of lithium, leading to increased serum lithium concentrations and toxicity. Serum lithium concentrations must be monitored closely.
Warfarin No significant pharmacokinetic change, but effect may be altered upon starting or stopping Azilsartan. Monitoring of International Normalized Ratio (INR) is required.

Co-administration with NSAIDs, including selective COX-2 inhibitors, carries a caution, particularly in volume-depleted or renally impaired patients, due to the risk of acute renal failure. The official labeling emphasizes that the co-use of potassium-elevating agents necessitates careful monitoring of serum potassium to manage the risk of hyperkalemia. Furthermore, regulatory documents explicitly require the monitoring of serum levels for lithium and the monitoring of coagulation parameters for warfarin, structuring the constraints for these combinations.

Mechanism of Action

How Azilsartan Works: Mechanism of Action

Azilsartan, an Angiotensin II Receptor Blocker (ARB), acts by precisely targeting a key component of the body's pressure regulation system, the Renin-Angiotensin-Aldosterone System (RAAS).

Selective AT1 Receptor Blockade

Azilsartan exerts its primary effect by being a selective antagonist of the Angiotensin Type 1 ( AT1) receptor. This binding action physically blocks the active vasoconstrictive hormone Angiotensin II from activating the receptor, thereby interrupting the central signaling cascade that promotes vascular contraction.

Modulation of Vascular Tone and Fluid Balance

By preventing AT1 receptor activation, Azilsartan limits signals that cause blood vessels to constrict, resulting in vasodilation (widening of the vessels). Additionally, this blockade lessens the Angiotensin II-driven release of aldosterone, which influences sodium and water retention by the kidneys, thus modulating systemic volume.

Reduction of Systemic Vascular Resistance

The combined effect of vasodilation and reduced fluid volume contributes to a decrease in systemic vascular resistance (SVR). This modulation of RAAS-mediated pathways influences cardiovascular activity by modulating the signaling mediated by Angiotensin II on regulatory systems.

Dosage and Administration Information

How to Use Azilsartan

This information describes the proper method for taking Azilsartan (Azilsartan medoxomil).

Dosing and Administration

Field Instruction
Route of Administration Oral use only. The tablet should be swallowed whole.
Dosing Frequency The medicine is taken once daily
Timing in Relation to Meals Azilsartan may be taken with or without food.

Standard Labeled Dosing

Dosing Parameter Official Guideline
Recommended Starting Dose (Adults) 40 mg once daily.
Maximum Daily Dose 80 mg once daily.
Dose Adjustment Considerations A lower starting dose of 20 mg may be considered for patients who are volume- or salt-depleted, or for very elderly patients (ge 75 years) who may be at risk of hypotension.

Procedural Notes

If a dose is missed, the procedure is to skip the missed dose and resume the regular dosing schedule at the next designated time. Do not take two doses to compensate for a missed one. No preparation steps (such as crushing, splitting, or dilution) are specified or generally permitted; the tablet is intended to be swallowed intact. The medication is used as a continuous regimen for long-term therapy.

Recent Clinical Evidence

Azilsartan: Recent Clinical Evidence

Research for High Blood Pressure (Hypertension)

Research examining Azilsartan has primarily focused on its use in studies involving high blood pressure, or hypertension. These studies are typically randomized, controlled trials where the outcomes reflecting daily functioning are carefully monitored, often using 24-hour ambulatory blood pressure monitoring (ABPM) in addition to clinic measurements. This approach allows researchers to observe how blood pressure levels evolve throughout defined time intervals, capturing phases of heightened symptom activity both during the day and at night.

The primary goal of these trials was studied for whether Azilsartan was associated with observed changes in blood pressure compared to an inactive substance (placebo) or compared to other established blood pressure medications. Research explored changes measured during the study period, and findings indicate that Azilsartan was studied for its association with measured blood pressure outcomes, which included changes in both systolic and diastolic numbers. In several studies, data show patterns related to observed differences in 24-hour mean systolic blood pressure when compared to certain other medications within the same class, such as valsartan and olmesartan. These findings describe patterns observed in the studies and help contextualize how the observed populations responded to the intervention.

What remains uncertain is the full extent of the long-term effects are not fully established on clinical outcomes, such as major cardiovascular events, as the follow-up durations were limited in many of these initial head-to-head comparison studies to several weeks or months. While the evidence suggests an association with measured outcomes over defined time intervals, data regarding long-term effects on outcomes like stroke or heart attack are still emerging, and certainty remains low.

Research in Specific Patient Groups

Studies have also explored the use of Azilsartan in specific patient groups, including those with conditions involving periods of heightened symptoms, such as adults with hypertension who also have Type 2 diabetes. This research examined whether Azilsartan was observed in managing blood pressure in this subgroup, which often faces more complex systemic or functional imbalance. The findings indicate that Azilsartan was associated with observed blood pressure changes in patients with both hypertension and Type 2 diabetes, with outcomes related to measured blood pressure that were similar to those seen in the general hypertensive population.

Comparative evidence is lacking for certain groups, particularly when comparing Azilsartan to every other available treatment option across different races or age categories. For example, while studies suggest that its effects was observed in some studies across different age groups (under 65 and 65 years and older), results apply only to the populations studied. Data for certain groups remain insufficient, such as those with advanced kidney disease or severe cardiac conditions, and the evidence quality varies across studies depending on the specific group being observed.

Limitations and Remaining Uncertainties

The existing evidence contributes to the broader evidence landscape for blood pressure patterns but also highlights several research limitation frames. Specifically, the majority of evidence focuses on measured physiological outcomes, but there is limited information for long-term outcomes related to preventing major life events. Furthermore, research describes other potential effects—sometimes referred to as "pleiotropic" effects—that was observed in preclinical settings is ongoing, and a clinical demonstration of these findings is not fully established.

Studies focusing on episodes where symptoms become more noticeable, such as severe, uncontrolled hypertension, often use combination therapy, which makes it challenging to isolate the effect of Azilsartan alone. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. It is important to remember that study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly. Long-term comparative evidence against every alternative treatment remains incomplete, suggesting that data are still emerging.

Key Studies & References Azilsartan - StatPearls (Source for regulatory context and general clinical guidelines)

Frequently Asked Questions (FAQ)

Common questions about Azilsartan (FAQ)

Q: How quickly does Azilsartan start to lower blood pressure?

A: The active component of Azilsartan reaches its peak concentration in the bloodstream within approximately 1.5 to 3 hours after taking the medicine. For patients on a once-daily regimen, stable blood levels—known as steady state—are typically achieved after about five days of continuous use.

Q: What is the typical time frame to see the full effect of Azilsartan?

A: Azilsartan is intended for chronic, long-term management of high blood pressure. While the drug is working in the body from the first dose, official product information indicates that stable therapeutic levels are generally reached after five days of continuous dosing.

Q: Is it normal for blood pressure to fluctuate when first starting Azilsartan?

A: When initiating treatment with Azilsartan, the official label cautions about the potential for Symptomatic Hypotension, or excessively low blood pressure. Regulatory warnings indicate that close monitoring of blood pressure changes may be necessary during initiation.

Q: How long does Azilsartan stay in the system?

A: The time it takes for half of the active substance to be eliminated from the body, known as the half-life, is approximately 11 hours. This pharmacokinetic characteristic supports the once-daily dosing schedule described in the official product information.

Q: What happens if I suddenly stop taking Azilsartan?

A: Azilsartan is a medicine intended for the long-term and continuous management of blood pressure. According to official documents, stopping the medicine suddenly may cause your blood pressure to increase again. The drug is intended for a continuous regimen, and regulatory bodies advise that discontinuation should be managed by a healthcare professional.

Q: Is Azilsartan a new or older type of blood pressure medicine?

A: Azilsartan is considered one of the newer agents in the Angiotensin II Receptor Blocker (ARB) pharmacological class. Regulatory bodies, such as the FDA, approved it after many other ARBs, designating it as the eighth drug of this type to enter the market.

Q: Does Azilsartan work differently than a diuretic?

A: Yes. Azilsartan is an ARB that acts by blocking a hormone receptor to widen blood vessels. Diuretics primarily work in the kidneys to increase the excretion of water and salt, which reduces fluid volume. This combination is a common strategy cited in official documentation to utilize complementary mechanisms for blood pressure management.

Q: What is Azilsartan medoxomil potassium?

A: Azilsartan medoxomil potassium is the complete chemical name for the drug substance used to manufacture the tablets. This nomenclature indicates that the medication is prepared as the potassium salt of the azilsartan medoxomil prodrug.

Q: What is the difference between Azilsartan and Olmesartan?

A: Regulatory clinical reviews have compared Azilsartan with other ARBs, including Olmesartan. Findings reported in regulatory materials indicate that in clinical studies, Azilsartan was associated with a greater measured reduction in 24-hour mean systolic blood pressure when compared to Olmesartan at its maximum approved dose.

Q: How is Azilsartan different from Losartan?

A: Azilsartan and Losartan are both classified in the same Angiotensin II Receptor Blocker (ARB) class, but Azilsartan is a newer agent. Regulatory documents note that in clinical trials, Azilsartan was associated with a greater reduction in measured blood pressure compared to Losartan when both were studied at their maximum approved doses.

Q: Why might a doctor switch me from another blood pressure medicine to Azilsartan?

A: Regulatory documentation describes Azilsartan as having a potent and persistent ability to block the Angiotensin II receptor compared to some older medications in the same class. The comparative trial data suggesting differences in blood pressure-lowering effects, combined with its pharmacological profile, represent factors described in regulatory reviews.

Q: Does Azilsartan interact with alcohol?

A: Official patient information indicates that alcohol can have an additive effect in lowering blood pressure. This combination may increase the risk of side effects associated with low blood pressure, such as dizziness or lightheadedness.

Q: Are there any restrictions on driving while taking Azilsartan?

A: Official patient information indicates that Azilsartan can potentially affect alertness or coordination because side effects like dizziness or fatigue are possible. The official product information indicates that patients should not drive or operate machinery until they are aware of how the medicine affects them.

Q: Can Azilsartan be taken with other blood pressure medicines?

A: Yes, Azilsartan is often prescribed in combination with other blood pressure medicines, most commonly diuretics. However, it is explicitly contraindicated (must not be used) in combination with aliskiren-containing products in patients with diabetes or moderate-to-severe kidney impairment.

Q: Why is Azilsartan sometimes taken in combination with a water pill?

A: The strategy of combining Azilsartan (an ARB) with a diuretic ('water pill') utilizes two distinct mechanisms of action to treat high blood pressure. Official documentation states that this approach is common because it leverages both pharmacological pathways for the management of blood pressure.

Q: Can Azilsartan cause swelling in the ankles or feet?

A: While swelling in the ankles or feet (peripheral edema) is not listed as a common expected side effect, official safety information mentions this as a symptom that may indicate a serious complication, such as a worsening of kidney function. The presence of new or worsening swelling is a symptom that official patient information indicates warrants attention from a healthcare professional.

Q: Is it safe to take Azilsartan before surgery?

A: Due to the risk of significant hypotension (very low blood pressure) during surgery when combined with general anesthesia, regulatory guidance suggests the medicine may need to be withheld 24 hours prior to an elective procedure. Decisions regarding administration before surgery are managed by the patient’s healthcare team, including the surgical and anesthesia specialists.

Q: Can I take Azilsartan with high cholesterol medications?

A: Clinical pharmacokinetic studies noted in regulatory documentation did not find a significant interaction between Azilsartan and the metabolism of certain high cholesterol medications known as statins. This indicates that co-administration is generally permitted, though such use is managed by a healthcare professional.

Q: Does Azilsartan have an impact on heart failure outcomes?

A: The official label primarily defines Azilsartan's role in treating hypertension. The information notes that patients with severe congestive heart failure are considered a high-risk group requiring careful monitoring. The label itself does not make definitive claims about the drug’s long-term effect on major heart failure outcomes.

Q: Does Azilsartan affect blood sugar levels?

A: Azilsartan is studied and used for high blood pressure management in patients who also have Type 2 diabetes. While clinical trials examine markers like blood glucose, the official product information does not make claims regarding the medicine's direct, therapeutic effect on blood sugar levels.

Q: Is there a patient information leaflet (PIL) available for Azilsartan?

A: Yes. As a prescription medicine approved by governmental health agencies, the product is mandated to be accompanied by official, patient-focused documents. These documents are generally referred to as a Patient Information Leaflet (PIL) or a Medication Guide.

Q: Are there any foods or drinks to avoid while taking Azilsartan?

A: Azilsartan may be taken with or without food. There are no specific food interactions mentioned in the official product information. However, because this medicine can affect potassium levels, the use of salt substitutes that contain potassium is generally cautioned by regulatory agencies.

How should Azilsartan be stored and disposed of?

How to Store and Dispose of Azilsartan?

Regulatory information dictates specific requirements for storing and disposing of azilsartan to ensure stability and safety.

Storage and Handling

Requirement Official Instruction
Temperature Store at controlled room temperature; keep from freezing.
Protection Keep in the original container to protect from light and moisture.
Safety Keep all medicine, including the container, out of the reach and sight of children.
Handling Do not repackage the product from its original container.

Disposal

Do not keep outdated or no longer needed medicine. To dispose of azilsartan properly, ask a healthcare professional or pharmacist for guidance on local take-back programs or safe disposal procedures. Do not allow the medication to enter sewers, surface water, or groundwater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Azilsartan found in:

A-Z Index: